A study on Egyptian CML patients noted that rs3442524, one out of three studied TET2 SNPs (rs2454206, rs34402524, rs61744960) was associated with larger spleen size and higher BCR-ABL1 levels after six months of starting treatment with tyrosine kinase inhibitors, without altering the prognostic criteria of patients. The gene discussed is TET2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.